[BRCA-like breast cancer patients benefit from cisplatin plus veliparib-results from the S1416 phase II study]

Related Experiment Video

Updated: Jul 13, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Katharina Hintelmann1, Kerstin Borgmann2

  • 1Ambulanzzentrum der UKE GmbH, Fachbereich Strahlentherapie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. ka.hintelmann@uke.de.

Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|October 12, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

Related Experiment Videos

Last Updated: Jul 13, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

Effects of intrafractional motion on targeting accuracy in frameless single-isocenter multi-target stereotactic radiosurgery.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Circulating microRNA Profiles as Diagnostic Tools for High-Grade Cervical Lesions and HPV Genotype Stratification.

Cells·2026

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients.

Molecular oncology·2026

Bi-allelic WDHD1 variants cause microcephalic primordial dwarfism.

American journal of human genetics·2026

ESTRO's principles for environmental sustainability in the radiation oncology community.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer.

Breast cancer research : BCR·2025

Patient preferences and travel burden before radiotherapy for primary cutaneous lymphoma: baseline results from the S-MISR registry.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Comparative toxicity and efficacy of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: real-world retrospective cohort study.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Evaluation of PET-detected nodal upstaging and planning target volume expansion in esophageal cancer radiotherapy planning.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Increased number of chemotherapy cycles during radiochemotherapy improves overall survival without increasing toxicity in locally advanced non-small cell lung cancer patients.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Tightening the gradient: ten years of dosimetric refinement in head and neck reirradiation.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Outcomes in long-term survivors treated with stereotactic cranial radiotherapy for brain metastases.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us